Cargando…

Isocitrate dehydrogenase 1 Gene Mutation Is Associated with Prognosis in Clinical Low-Grade Gliomas

Isocitrate dehydrogenase 1 gene mutations are found in most World Health Organization grade II and III gliomas and secondary glioblastomas. Isocitrate dehydrogenase 1 mutations are known to have prognostic value in high-grade gliomas. However, their prognostic significance in low-grade gliomas remai...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Ming-Yang, Wang, Yin-Yan, Cai, Jin-Quan, Zhang, Chuan-Bao, Wang, Kuan-Yu, Cheng, Wen, Liu, Yan-Wei, Zhang, Wei, Jiang, Tao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4482584/ https://www.ncbi.nlm.nih.gov/pubmed/26115094 http://dx.doi.org/10.1371/journal.pone.0130872

Ejemplares similares

Clinico-neuropathological features of isocitrate dehydrogenase 2 gene mutations in lower-grade gliomas
por: Wang, Lei-Ming, et al.
Publicado: (2019)

Immunotherapy Approaches in Isocitrate-Dehydrogenase-Mutant Low-Grade Glioma
por: Gallus, Marco, et al.
Publicado: (2023)

Advances in Immune Microenvironment and Immunotherapy of Isocitrate Dehydrogenase Mutated Glioma
por: Yan, Dongming, et al.
Publicado: (2022)

Screening of Methylation Signature and Gene Functions Associated With the Subtypes of Isocitrate Dehydrogenase-Mutation Gliomas
por: Pan, XiaoYong, et al.
Publicado: (2019)

Ivosidenib in Isocitrate Dehydrogenase 1–Mutated Advanced Glioma
por: Mellinghoff, Ingo K., et al.
Publicado: (2020)

Isocitrate Dehydrogenase Mutations in Glioma: Genetics, Biochemistry, and Clinical Indications
por: Liu, Yang, et al.
Publicado: (2020)

EGFRvIII expression and isocitrate dehydrogenase mutations in patients with glioma
por: Taher, Mohiuddin M., et al.
Publicado: (2020)

Isocitrate dehydrogenase mutations in gliomas: A review of current understanding and trials
por: Sharma, Nikhil, et al.
Publicado: (2023)

Influence of scalp block on oncological outcomes of high-grade glioma in adult patients with and without isocitrate dehydrogenase-1 mutation
por: Sung, Chao-Hsien, et al.
Publicado: (2021)

Isocitrate Dehydrogenase Mutations in Glioma: From Basic Discovery to Therapeutics Development
por: Huang, Juan, et al.
Publicado: (2019)

Mutated Isocitrate Dehydrogenase (mIDH) as Target for PET Imaging in Gliomas
por: Neumaier, Felix, et al.
Publicado: (2023)

Integrated analysis of the genomic and transcriptional profile of gliomas with isocitrate dehydrogenase-1 and tumor protein 53 mutations
por: Liu, Han-Qing, et al.
Publicado: (2022)

Amide Proton Transfer Imaging in Predicting Isocitrate Dehydrogenase 1 Mutation Status of Grade II/III Gliomas Based on Support Vector Machine
por: Han, Yu, et al.
Publicado: (2020)

N6-methyladenosine-related microRNAs risk model trumps the isocitrate dehydrogenase mutation status as a predictive biomarker for the prognosis and immunotherapy in lower grade gliomas
por: Yuan, Feng, et al.
Publicado: (2022)

Mutation of Isocitrate Dehydrogenase 1 in Cholangiocarcinoma Impairs Tumor Progression by Inhibiting Isocitrate Metabolism
por: Su, Li, et al.
Publicado: (2020)

Isocitrate dehydrogenase 1 (IDH1) mutation-specific microRNA signature predicts favorable prognosis in glioblastoma patients with IDH1 wild type
por: Wang, Zheng, et al.
Publicado: (2013)

Mechanisms underlying the biological changes induced by isocitrate dehydrogenase-1 mutation in glioma cells
por: WANG, JU-BO, et al.
Publicado: (2014)

Chromatin-regulating genes are associated with postoperative prognosis and isocitrate dehydrogenase mutation in astrocytoma
por: Zhang, Kun, et al.
Publicado: (2020)

Isocitrate dehydrogenase 1 mutation subtypes at site 132 and their translational potential in glioma
por: Lu, Victor M, et al.
Publicado: (2018)

Isocitrate dehydrogenase 1 mutation is associated with reduced levels of inflammation in glioma patients
por: Auezova, Raushan, et al.
Publicado: (2019)

Hub gene identification and prognostic model construction for isocitrate dehydrogenase mutation in glioma
por: Jia, Yanfei, et al.
Publicado: (2020)

Advanced multiparametric MRI-based scoring for isocitrate dehydrogenase mutation prediction of gliomas
por: Hosur, Bharat, et al.
Publicado: (2022)

Isocitrate dehydrogenase mutations in myeloid malignancies
por: Medeiros, B C, et al.
Publicado: (2017)

Using radiomics based on multicenter magnetic resonance images to predict isocitrate dehydrogenase mutation status of gliomas
por: Liu, Yan, et al.
Publicado: (2023)

The presence of TIM‐3 positive cells in WHO grade III and IV astrocytic gliomas correlates with isocitrate dehydrogenase mutation status
por: Sørensen, Mia D., et al.
Publicado: (2021)

5-Hydroxymethylcytosine preferentially targets genes upregulated in isocitrate dehydrogenase 1 mutant high-grade glioma
por: Glowacka, Wioletta K., et al.
Publicado: (2018)

Adult isocitrate dehydrogenase–mutant brainstem glioma: illustrative case
por: Ye, Vincent C., et al.
Publicado: (2021)

Rapid detection of isocitrate dehydrogenase 1 mutation status in glioma based on Crispr-Cas12a
por: Feng, Zhebin, et al.
Publicado: (2023)

TERT Mutation Is Accompanied by Neutrophil Infiltration and Contributes to Poor Survival in Isocitrate Dehydrogenase Wild-Type Glioma
por: Gao, Mengqi, et al.
Publicado: (2021)

A Non-invasive Radiomic Method Using (18)F-FDG PET Predicts Isocitrate Dehydrogenase Genotype and Prognosis in Patients With Glioma
por: Li, Longfei, et al.
Publicado: (2019)

An Analysis of the Prognostic Value of IDH1 (Isocitrate Dehydrogenase 1) Mutation in Polish Glioma Patients
por: Lewandowska, Marzena Anna, et al.
Publicado: (2013)

Characteristics of the isocitrate dehydrogenase gene and telomerase reverse transcriptase promoter mutations in gliomas in Chinese patients
por: Qu, Chong‐Xiao, et al.
Publicado: (2020)

Isocitrate Dehydrogenase IDH1 and IDH2 Mutations in Human Cancer: Prognostic Implications for Gliomas
por: Murugan, A. K., et al.
Publicado: (2022)

2-Hydroxyglutarate Production, but Not Dominant Negative Function, Is Conferred by Glioma-Derived NADP(+)-Dependent Isocitrate Dehydrogenase Mutations
por: Jin, Genglin, et al.
Publicado: (2011)

Evaluation of isocitrate dehydrogenase mutation in 2021 world health organization classification grade 3 and 4 glioma adult-type diffuse gliomas with 18F-fluoromisonidazole PET
por: Wang, Yang, et al.
Publicado: (2023)

Radiological Prediction of Isocitrate Dehydrogenase (IDH) Mutational Status and Pathological Verification for Lower-Grade Astrocytomas
por: Yano, Hirohito, et al.
Publicado: (2022)

Multiparametric Magnetic Resonance Imaging Correlates of Isocitrate Dehydrogenase Mutation in WHO high-Grade Astrocytomas
por: Sahu, Arpita, et al.
Publicado: (2022)

Pre-operative Neurocognitive Function Was More Susceptible to Decline in Isocitrate Dehydrogenase Wild-Type Subgroups of Lower-Grade Glioma Patients
por: Zhang, Zhe, et al.
Publicado: (2020)

Isocitrate dehydrogenase mutations: new opportunities for translational research
por: Keum, Young-Sam, et al.
Publicado: (2015)

Metabolic adaptations in cancers expressing isocitrate dehydrogenase mutations
por: Hvinden, Ingvild Comfort, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9jpj3eo8ofgcmrbrl2d7js2m4s